Goldman Sachs’s Alexza Pharmaceuticals Inc ALXA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q2 | – | Sell |
-432,822
| Closed | -$210K | – | 7467 |
|
|
2016
Q1 | $210K | Buy |
432,822
+30,058
| +7% | +$13.2K | ﹤0.01% | 5576 |
|
|
2015
Q4 | $282K | Sell |
402,764
-419
| -0.1% | -$432 | ﹤0.01% | 5406 |
|
|
2015
Q3 | $496K | Sell |
403,183
-9,357
| -2% | -$10.9K | ﹤0.01% | 5146 |
|
|
2015
Q2 | $450K | Sell |
412,540
-59,947
| -13% | -$90K | ﹤0.01% | 5300 |
|
|
2015
Q1 | $978K | Sell |
472,487
-34
| -0% | -$70 | ﹤0.01% | 4509 |
|
|
2014
Q4 | $704K | Sell |
472,521
-13,613
| -3% | -$24.3K | ﹤0.01% | 4942 |
|
|
2014
Q3 | $1.13M | Sell |
486,134
-495
| -0.1% | -$1.89K | ﹤0.01% | 4477 |
|
|
2014
Q2 | $2.22M | Buy |
486,629
+28,935
| +6% | +$125K | ﹤0.01% | 3883 |
|
|
2014
Q1 | $2.03M | Sell |
457,694
-11,260
| -2% | -$57.7K | ﹤0.01% | 3955 |
|
|
2013
Q4 | $2.22M | Buy |
468,954
+394,434
| +529% | +$1.94M | ﹤0.01% | 3965 |
|
|
2013
Q3 | $382K | Sell |
74,520
-2,399
| -3% | -$11.3K | ﹤0.01% | 5377 |
|
|
2013
Q2 | $334K | Buy |
+76,919
| New | +$349K | ﹤0.01% | 5258 |
|
Goldman Sachs's ALXA Position: Q2 2016 in Review
Goldman Sachs sold out of Alexza Pharmaceuticals Inc (ALXA) in Q2 2016, closing a stake of 432,822 shares — an estimated $210K sold.
Goldman Sachs first reported a position in ALXA in Q2 2013 and held it in 12 quarters. The position peaked at $2.22M in Q2 2014. 0 funds tracked by Wall St. Rank hold ALXA as of Q2 2016.
- Goldman Sachs reported no remaining Alexza Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
- Goldman Sachs sold 432,822 Alexza Pharmaceuticals Inc shares in Q2 2016, an estimated $210K.
- Goldman Sachs first reported a position in Alexza Pharmaceuticals Inc in Q2 2013 and held it in 12 quarters.
- Goldman Sachs's Alexza Pharmaceuticals Inc position peaked at $2.22M in Q2 2014.
- 0 funds tracked by Wall St. Rank held Alexza Pharmaceuticals Inc as of Q2 2016.
Based on Goldman Sachs's 13F filing for Q2 2016, filed 15 Aug 2016.